Search Filters

Search Results

Found 44 results

510(k) Data Aggregation

    Why did this record match?
    510k Summary Text (Full-text Search) :

    II, Cortical electrode

    • K183123 - microTargeting Guideline 4000 5.0 System, FHC, Inc., 21 CFR 882.1330
      -------------------------|---------------------------|---------|
      | Classification Number | 882.1310 882.1330
      | 882.1310 | 882.1330 | Similar |
      | Indications for Use (IFU) statement | The ATLAS Stim Headbox is
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The ATLAS Stim Headbox is a low power, constant current or voltage mode, bi-phasic stimulator intended for cortical or intracranial stimulation during electroencephalography examinations (i.e. stereoEEG).

    The stimulation is applied to the brain using third-party stimulation probes (including cortical or intracranial electrodes) and the resulting cortical or deep brain potentials themselves are recorded using third-party cortical or intracranial electrodes.

    The ATLAS Stim Headbox itself is an accessory to the ATLAS Neurophysiology System and ATLAS STIM Headbox software. The stimulation parameters, the electrodes selection and the activation of the stimulation current are all set-up and controlled from these devices. The ATLAS Stim Headbox can operate only when so connected and with the Pegasus and ATLAS Stim Headbox software; it cannot serve as a stand-alone stimulator.

    Device Description

    The ATLAS Stim Headbox (ASHB) is a clinical headbox that allows 3rd party Macro electrode contact electrode arrays (ECoG, depth electrodes, grid array, strip array, etc.) to interface with the Neuralynx ATLAS Neurophysiology System, previously cleared in 510(k) K110967, which includes the Pegasus Software.

    The ATLAS Stim Headbox is an accessory to the ATLAS Neurophysiology System (formerly known as SpikeTrax in K110967). The ATLAS Stim Headbox hardware consists of an encased amplifier and embedded firmware for generation and delivery of stimulation energy. The ATLAS Stim Headbox can deliver electrical stimulation current under the control of the associated ATLAS Stim Headbox Software which interfaces via a fiber optic ethernet communications connection.

    AI/ML Overview

    The provided FDA 510(k) clearance letter and summary for the ATLAS Stim Headbox do not contain information about acceptance criteria or a study proving the device meets said criteria in the context of clinical performance or diagnostic accuracy. Instead, the document focuses on demonstrating substantial equivalence to predicate devices through technical comparisons and non-clinical performance testing (electrical safety, mechanical integrity, evoked response, electroencephalograph, and software regression).

    Therefore, I cannot fulfill most of your request regarding acceptance criteria, reported device performance, sample sizes, expert qualifications, adjudication methods, MRMC studies, standalone performance, or ground truth details.

    The document primarily covers the safety and basic functional performance of the hardware and software as a medical device accessory, not its diagnostic or therapeutic accuracy for specific clinical outcomes that would require clinical studies with ground truth.

    Here's a breakdown of what can be extracted from the provided text, and where information is missing:


    1. A table of acceptance criteria and the reported device performance

    The document does not present "acceptance criteria" in the sense of a clinical benchmark (e.g., sensitivity, specificity, accuracy) for a diagnostic output. Instead, it describes compliance with recognized standards and successful completion of verification and validation tests for safety and technical performance.

    Acceptance Criterion (Inferred/Stated)Reported Device Performance
    Electrical SafetyConsistent with IEC 60601 (Class 1 ME Equipment)
    Mechanical IntegrityConsistent with standard IEC 60601
    Evoked Response PerformanceConsistent with standard IEC 60601 and particular standard 60601-2-40
    Electroencephalograph PerformanceConsistent with standard IEC 60601 particular standard 80601-2-26
    Software Regression Testing (Functionality & Bug Fixes)Successfully performed iteratively at each software release per IEC 62304; bugs fixed assessed for effectiveness and risk.
    Charge per Pulse Phase LimitEnforces a rule limiting charge per pulse phase to less than 20µC. (Satisfies safety concerns despite longer pulse width.)
    Instantaneous Net Sum of CurrentsEnforces that at any instantaneous moment, the net sum of all currents flowing from all channels between the stimulator and the patient is zero. (Mitigates risk of increased cumulative current from more channels.)
    Compliance with Updated StandardsConforms to updated versions of FDA-recognized standards (IEC 60601 series, IEC 62304, IEC 62366).

    2. Sample sized used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)

    This information is not provided as the validation performed is non-clinical (device testing against engineering specifications and international standards), not a clinical study on patient data.

    3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)

    This information is not applicable/provided. The ground truth for device performance in this context is defined by international standards (e.g., IEC 60601) and engineering specifications. No clinical expert adjudication was mentioned for device functionality.

    4. Adjudication method (e.g. 2+1, 3+1, none) for the test set

    This information is not applicable/provided. No clinical adjudication method was mentioned for device functionality.

    5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

    An MRMC study was not done. The device is an accessory for stimulation and recording of neural activity, not an AI-powered diagnostic tool for interpretation by human readers.

    6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

    This is not applicable in the context of an "algorithm only" performance for a diagnostic task. The ATLAS Stim Headbox is a hardware accessory with embedded firmware and associated software, designed to be used in conjunction with other systems and by clinical professionals. It cannot operate as a stand-alone stimulator, as explicitly stated: "it cannot serve as a stand-alone stimulator."

    7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)

    The "ground truth" for the device's substantial equivalence and safety is primarily based on:

    • International standards and engineering specifications: Compliance with IEC 60601 series, IEC 62304, IEC 62366.
    • Functional verification: Demonstrating that the device's electrical characteristics (e.g., charge per phase, instantaneous current sum) meet safety limits and design specifications.
    • Predicate device characteristics: The claim of substantial equivalence is made against the technical specifications and known performance of the predicate devices.

    8. The sample size for the training set

    This is not applicable/provided. The document describes a hardware device and its control software. There is no mention of "training set" in the context of machine learning for a diagnostic algorithm. Software regression testing refers to the iterative testing of the software itself against predefined functionalities and bug fixes, not the training of a model on a dataset.

    9. How the ground truth for the training set was established

    This is not applicable/provided as there is no "training set" in the context of machine learning for a diagnostic algorithm.

    Ask a Question

    Ask a specific question about this device

    K Number
    K250601
    Date Cleared
    2025-03-30

    (30 days)

    Product Code
    Regulation Number
    882.1330
    Reference & Predicate Devices
    Why did this record match?
    510k Summary Text (Full-text Search) :

    Israel

    Re: K250601

    Trade/Device Name: Neuro Omega System; NeuroSmart System Regulation Number: 21 CFR 882.1330
    , GWQ, GYC |
    | CFR section: | 21 CFR 882.1330
    |
    | CFR section: | 21 CFR 882.1330

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    Neuro Omega System:

    The Neuro Omega System with the incorporated HaGuide Software, including the Drive Headstage unit, is intended to assist neurosurgeons in the operating room during functional neurosurgery and to record from and stimulate brain motor and sensory neurons and to aid in the placement of depth electrodes.

    The Neuro Omega System with the incorporated HaGuide Software is also intended:

    • To monitor, record, and display the bioelectric signals produced by muscles, to stimulate peripheral nerves, and to monitor, record, and display the electrical activity produced by nerves to aid the clinician in the diagnosis and prognosis of neuromuscular disease (EMG).

    • To measure, record, and display the electrical activity of the patient's brain obtained from two or more electrodes on the head (EEG).

    • To measure, display and record the electrical activity of the patient's brain obtained from ECOG strip and grid electrodes.

    • To provide stimulation via electrode pairs or a hand-held bipolar probe for use in functional brain mapping procedures during treatment of patients with a seizure disorder.

    The Neuro Omega System with the incorporated installed HaGuide Software, is intended for intraoperative use by medical personnel. Within hospitals, laboratories, clinics, or nursing home settings or outside of a medical facility under the direct supervision of a medical professional. The device may also be placed in the intensive care unit or operating room for continuous recording.

    NeuroSmart System:

    The NeuroSmart System with the incorporated HaGuide Software, is intended to be used in assisting neurosurgeons, in the operating room during functional neurosurgery, to record from and stimulate brain motor and to aid in the placement of depth electrodes

    Device Description

    The cleared devices under K220553, the HaGuide Software incorporated in Neuro Omega/NeuroSmart systems, is designed to detect the STN region, it detects the entrance and exit boundaries of STN regions. Furthermore, it presents real-time graphs of power spectrum density and the normalized root mean square (nRMS) of the region. The HaGuide Software consists of the following components:

    • Patient Dashboard: The Patient Dashboard is comprised of a list of patients/cases that the user added, providing a user-friendly way to manage the surgery cases.
    • Planning Setup: The Planning Setup is used by the user to setup the surgery planning.
    • Trajectory Setup: The Trajectory Setup is used by the user to setup trajectory.
    • MER/HaGuide: MER/HaGuide is comprised of:
      • Real-time Microelectrode Recording (MER) signal processing, presented as o Normalized Root Mean Square (NRMS) and Power Spectrum Density (PSD) graphs, to assist the user to interpret the signals.
      • MER notes taking adding notes and tags to specific site location to o document and annotate the signals.
      • HaGuide Recommendation: Detection of the Subthalamic Nucleus (STN) o borders, including the Intra STN detection of Dorsolateral Oscillatory Region (DLOR) and Ventromedial Non-Oscillatory Region (VMNR) boundary.
    • Operation Room Report Upload – Cloud: The OR report uploading feature is used to export the case data and HaGuide graphs and HaGuide recommendation securely to the cloud.
    • Raw Data Upload – Cloud: The raw data uploading feature is used to upload the raw recording data files securely to the cloud for offline processing

    The HaGuide Software can work in three setups:

      1. The HaGuide Software can be installed on the Neuro Omega/NeuroSmart PC and used on the system.
      1. The HaGuide Software can be installed on an external PC as a standalone software for the purpose of working in off-line mode with no connection to the system.

    In all setups the safety and effectiveness of the Neuro Omega/NeuroSmart systems isn't compromised, as the HaGuide Software is a non-blocking software (it doesn't affect the system's functionality even in malfunction). The HaGuide Software can run on both modes without affecting the Neuro Omega/NeuroSmart systems safety and effectiveness, nor its functionality.

    AI/ML Overview

    The provided text describes the regulatory clearance for the Neuro Omega System and NeuroSmart System, which incorporate the HaGuide Software. It focuses heavily on the software as a standalone component and its integration with the existing systems.

    Based on the provided text, the study proving the device meets acceptance criteria is primarily non-clinical performance testing of the HaGuide Software and its integration with the Neuro Omega/NeuroSmart systems, rather than a clinical study evaluating human-in-the-loop performance or diagnostic accuracy with ground truth from clinical data.

    Here's an analysis of the requested information based on the provided text:

    1. Table of Acceptance Criteria and Reported Device Performance

    Test PerformedAcceptance CriteriaReported Device Performance
    Software / System VerificationThe acceptance criteria were defined according to the use cases and regressions tests performed by the Neuro Omega / NeuroSmart systems, to ensure proper functionality:
    • HaGuide SW integration with Alpha Omega cloud is tested.
    • The verification tests cover the design inputs (SRS) as well as use cases and sanity tests. | All tests passed the acceptance criteria. |
      | Penetration Testing | The identified risks are determined, then the scales are passed in accordance to NIST SP 800-30r1. | Overall cybersecurity risks related to Confidentiality, Integrity, and Availability have been evaluated. This includes risks related to software supply chain. Any risks introduced by risk controls were evaluated and mitigated to an acceptable level. |
      | EMC Reports (IEC 60601-1-2) | The subject devices are safe and effective and meet the requirements of IEC 60601-1-2:2014, IEC 60601-1-2:014/AMD1:2020. | All tests passed the acceptance criteria. |
      | Safety Reports (IEC 60601-1) | Neuro Omega/NeuroSmart systems incorporated the HaGuide Software are safe and effective and meet the requirements of IEC 60601-1:2005, IEC 60601-1:2005/AMD1:2012, IEC 60601-1:2005/AMD2:2020. | All tests passed the acceptance criteria. |

    Note: The provided document describes non-clinical performance tests focused on software verification, cybersecurity, electromagnetic compatibility (EMC), and electrical safety. It does not contain information about clinical performance such as diagnostic accuracy, sensitivity, or specificity in a medical context. The "HaGuide Recommendation" feature for STN border detection is mentioned, but no specific performance metrics or clinical study results for this feature are provided in the excerpt. The submission is framed as a 510(k) for a "new infrastructure and GUI" of the HaGuide software, maintaining the same purpose as the predicate, which implies a focus on demonstrating that the changes do not introduce new safety or effectiveness issues, rather than proving new clinical effectiveness.

    2. Sample Size Used for the Test Set and Data Provenance

    • Test Set Sample Size: Not explicitly stated as a "sample size" in the context of clinical data. The tests performed are engineering-focused:
      • Software/System Verification: This involves internal regression tests and testing against "use cases and sanity tests." The number of test cases or specific data points tested is not enumerated.
      • Penetration Testing: This involves analyzing and identifying risks, not a numerical "test set" of patient data.
      • EMC/Safety Reports: These are engineering compliance tests performed on the physical devices.
    • Data Provenance: Not applicable in the context of clinical data for these non-clinical performance tests. The document does not describe the use of patient data for testing device performance related to medical diagnosis or treatment. The HaGuide Software's ability to "detect the STN region" and present "real-time graphs of power spectrum density and the normalized root mean square (nRMS)" suggests it processes physiological signals, but how these processed signals were specifically "tested" for accuracy against a clinical ground truth is not detailed in this section. The mention of "Raw Data Upload – Cloud" for "offline processing" suggests data collection, but not its use as a test set for a performance study.

    3. Number of Experts Used to Establish Ground Truth for the Test Set and Their Qualifications

    Not applicable. The provided document describes non-clinical performance tests, not a clinical study involving human experts establishing ground truth for patient data.

    4. Adjudication Method for the Test Set

    Not applicable. There is no mention of a clinical test set requiring adjudication.

    5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done

    No. The document does not describe an MRMC study or any clinical comparative effectiveness study involving human readers with and without AI assistance. The focus is on the functional verification and safety of the software and system.

    6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done

    The HaGuide Software is described as having a "standalone software" mode for "off-line processing" and for "visual purpose only, meaning receive data from the systems and present it in graphs." While it can run in standalone mode, the "performance" described in the acceptance criteria table is for functional verification, cybersecurity, and electrical safety, not for a standalone clinical performance evaluation of its algorithms (e.g., accuracy of STN detection). The document states, "No changes are made to the retrieved data. Furthermore, the data will be used for verification only for the neurologist prior to fine-tuning the IPG work mode by using the IPG interface (not Alpha Omega's device)." This suggests the software provides information to clinicians, but its algorithmic accuracy in providing medical insights is not the subject of the detailed performance tests presented.

    7. The Type of Ground Truth Used

    For the reported non-clinical performance tests:

    • Software/System Verification: Ground truth is established by the defined "design inputs (SRS) as well as use cases and sanity tests." This is based on functional and technical specifications, not clinical outcomes or expert consensus.
    • Penetration Testing: Ground truth is against cybersecurity best practices and standards (e.g., NIST SP 800-30r1).
    • EMC/Safety Reports: Ground truth is against established international standards (IEC 60601-1-2 and IEC 60601-1).

    No clinical ground truth (e.g., pathology, surgical findings, long-term outcomes, or expert consensus on clinical images/signals) is mentioned as being used for the performance evaluation described.

    8. The Sample Size for the Training Set

    Not applicable. The document does not describe the use of machine learning or deep learning models that would require a "training set" for the HaGuide Software's core functionality. While the software "detects the STN region," it's not specified if this detection relies on a trained AI model or deterministic algorithms. The "new infrastructure and GUI" suggests software updates rather than new AI model development requiring a training set.

    9. How the Ground Truth for the Training Set Was Established

    Not applicable, as no training set for an AI model is described.

    Ask a Question

    Ask a specific question about this device

    K Number
    K230853
    Date Cleared
    2023-10-06

    (192 days)

    Product Code
    Regulation Number
    874.1820
    Reference & Predicate Devices
    Why did this record match?
    510k Summary Text (Full-text Search) :

    | GZL (21 CFR 882.1330

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The EARP Nerve Cuff Electrode is used to perform localized stimulation of neural tissue and to locate, identify, and monitor spinal nerve roots during surgery.

    Device Description

    The EARP Nerve Cuff Electrode conducts electrical signal as a component of intraoperative neuromonitoring. The EARP Nerve Cuff Electrode is used with commercially available neuromonitoring systems and does not stimulate or record signal itself. The standard connectors at the proximal end of the EARP Nerve Cuff Electrode interface with the neuromonitoring equipment and the distal cuff contacts the target tissue. The EARP Nerve Cuff Electrode is provided sterile packaged and is for single use only.

    AI/ML Overview

    The provided text describes the 510(k) summary for the EARP Nerve Cuff Electrode, a surgical nerve stimulator/locator. It does not pertain to an AI/ML medical device, but rather a physical medical device. Therefore, many of the requested elements for describing the acceptance criteria and study proving an AI/ML device's performance are not present in this document.

    However, I can extract the information related to the acceptance criteria and the study that proves the physical device meets these criteria, based on the provided FDA 510(k) summary.

    Here's an attempt to answer as much as possible given the limitations of the provided text, recognizing that it's for a traditional medical device, not an AI/ML one:

    Acceptance Criteria and Device Performance for the EARP Nerve Cuff Electrode

    Since this is a physical medical device submission, the "acceptance criteria" are based on non-clinical performance and biocompatibility testing, demonstrating the device's safety and effectiveness in its intended use, and its substantial equivalence to predicate devices. The "study" refers to the non-clinical testing performed.

    1. A table of acceptance criteria and the reported device performance

    The document lists "Summary of Non-Clinical Testing" which serves as the "study" proving the device meets the acceptance criteria. The acceptance criteria are implied by the "Conclusion" column (e.g., "no evidence of causing cell lysis or toxicity" for cytotoxicity), and the "Pass/Fail" column indicates whether the device met these criteria.

    Acceptance Criteria (Implied)Reported Device Performance (Conclusion)Pass/Fail
    Biocompatibility Testing:
    Cytotoxicity (ISO 10993-5): No evidence of cell lysis or toxicityThe test article extract showed no evidence of causing cell lysis or toxicity. The test article extract met the requirements of the test since the grade was less than a grade 2 (mild reactivity).Pass
    Sensitization (ISO 10993-10): No delayed dermal contact sensitizationThe test article extracts showed no evidence of causing delayed dermal contact sensitization in the guinea pig. The test article was not considered a sensitizer in the guinea pig maximization test.Pass
    Irritation (ISO 10993-23): Acceptable difference in mean scoresThe test article met the requirements of the test since the difference between each test article extract overall mean score and corresponding control extract overall mean score was 0.0 and 0.1 for the SC and SO test article extracts, respectively.Pass
    Acute Systemic Toxicity (ISO 10993-11): No mortality or systemic toxicityThere was no mortality or evidence of systemic toxicity from the extracts injected into mice. Each test article extract met the requirements of the study.Pass
    Material-Mediated Pyrogenicity (USP, ISO 10993-11): Acceptable rise in rabbit temperaturesThe total rise of rabbit temperatures during the 3 hour observation period was within acceptable USP requirements. The test article met the requirements for the absence of pyrogens.Pass
    Other Non-Clinical Testing:
    Dimensional characteristics, materials, function, intended useEvaluated to ensure it performed as intended and supported substantial equivalence to predicate devices. (Specific performance values not detailed, but implied as 'Pass' overall.)Pass
    Tensile and flexural testing (mechanical integrity, continuity, isolation, visual appearance)Evaluated to ensure it performed as intended and supported substantial equivalence to predicate devices. (Specific performance values not detailed, but implied as 'Pass' overall.)Pass
    Electrical safety testing (high potential and electrical leakage per ISO 14708-1)Evaluated to ensure it performed as intended and supported substantial equivalence to predicate devices. (Specific performance values not detailed, but implied as 'Pass' overall.)Pass
    Electrode lead wire performance per 21 CFR 898.12 (IEC 60601-1)Evaluated to ensure it performed as intended and supported substantial equivalence to predicate devices. (Specific performance values not detailed, but implied as 'Pass' overall.)Pass

    2. Sample size used for the test set and the data provenance

    • Sample Size: The document does not specify the exact sample sizes (e.g., number of units, animals, or test replicates) for each test. It mentions "mice" and "guinea pig" for specific biocompatibility tests, implying the use of animal models according to the ISO standards.
    • Data Provenance: The provenance is through laboratory testing conducted on the device components or extracts. The document does not specify the country of origin where the tests were performed, nor whether the data involved retrospective or prospective collection of patient data, as this is laboratory testing of a physical device.

    3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts

    This concept is not applicable to the type of device described. "Ground truth" established by experts is typically relevant for interpretative devices like AI/ML products where human experts provide labels or diagnoses for comparison. For a physical medical device like an electrode, the "ground truth" is established by adherence to recognized performance standards (e.g., ISO, IEC, USP) and validated laboratory test methodologies. The "experts" would be the qualified personnel performing and interpreting these specific laboratory tests.

    4. Adjudication method for the test set

    This concept is not applicable as there is no "adjudication" of human interpretations for this type of device. The results are based on objective measurements from standardized laboratory tests.

    5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

    This concept is not applicable as this is not an AI/ML device, and no human reader study was performed.

    6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

    This concept is not applicable as this is not an AI/ML device and does not involve an algorithm. The device's "standalone" performance is assessed through its physical characteristics and electrical/biocompatibility safety in laboratory settings.

    7. The type of ground truth used

    The "ground truth" for this physical device is established by:

    • Established Performance Standards: Adherence to ISO, IEC, and USP standards for biocompatibility, electrical safety, and mechanical integrity.
    • Objective Measurements: Laboratory measurements of physical, chemical, and electrical properties compared against pre-defined specifications derived from these standards or engineering requirements.

    8. The sample size for the training set

    This concept is not applicable as this is not an AI/ML device that requires a training set.

    9. How the ground truth for the training set was established

    This concept is not applicable as this is not an AI/ML device that requires a training set.

    Ask a Question

    Ask a specific question about this device

    K Number
    K223276
    Date Cleared
    2023-05-18

    (206 days)

    Product Code
    Regulation Number
    882.1330
    Reference & Predicate Devices
    Why did this record match?
    510k Summary Text (Full-text Search) :

    K223276

    Trade/Device Name: Anchor Bolts as Accessories to Depth Electrodes Regulation Number: 21 CFR 882.1330
    Classification Name: | Electrode, Depth |
    | Regulation Number: | 21 CFR 882.1330

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The Ad-Tech Anchor Bolts are optional accessories for use with Depth Electrodes. The Anchor Bolts may be applied when it is desired to minimize concerns about potential cerebrospinal fluid (CSF) leakage and infection of the subdural space while stabilizing the electrode. Anchor Bolts are secured in the skull to provide an access point for Depth Electrodes.

    Device Description

    The device under review is a family of Anchor Bolts. Anchor Bolts are optional accessories to Depth Electrodes. These Anchor Bolts provide an optional access point through the skull and stabilization support for Depth Electrodes.

    AI/ML Overview

    The furnished document is an FDA 510(k) Premarket Notification stating substantial equivalence for the "Anchor Bolts as Accessories to Depth Electrodes" device. It outlines the device description, intended use, comparison with a predicate device, and performance data related to its safety in the Magnetic Resonance (MR) environment.

    However, the information provided does not describe an AI medical device or a study involving human readers or AI assistance. The performance data is solely for the physical device's safety in an MR environment, not for an AI algorithm's diagnostic or assistive performance.

    Therefore, I cannot fulfill your request as it pertains to acceptance criteria and studies for an AI medical device, multi-reader multi-case studies, or AI algorithm performance.

    The document discusses the following acceptance criteria and performance for the physical device:

    1. Table of Acceptance Criteria and Reported Device Performance

    Hazard AddressedTest Method UsedAcceptance CriterionMedical Device Configuration TestedSummary of Test Results and pass/fail (if Appropriate)
    Image Artifact (1.5T)ASTM F2119-13No Criteria, Descriptive StatementDevice with the maximum mass/linear lengthAdoption from 3.0T tests since 3.0T is the worst-case.
    Magnetically Induced Displacement Force (1.5T)ASTM F2052-15
    Ask a Question

    Ask a specific question about this device

    K Number
    K223269
    Date Cleared
    2023-05-18

    (206 days)

    Product Code
    Regulation Number
    882.1330
    Reference & Predicate Devices
    Why did this record match?
    510k Summary Text (Full-text Search) :

    Minnesota 55426

    Re: K223269

    Trade/Device Name: Spencer Probe Depth Electrodes Regulation Number: 21 CFR 882.1330
    Specialty: 510(k) Review Panel:

    Depth Electrodes (Spencer Probe Depth Electrode) Electrode, Depth 21 CFR 882.1330
    |
    | Regulation Number: | 21 CFR 882.1330

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The AD-TECH Depth Electrodes (Spencer Probe Depth Electrodes) are intended for temporary (

    Device Description

    The Depth Electrodes (Spencer Probe Depth Electrode) are intended for recording, monitoring and stimulation at sub-surface levels of the brain. These electrodes are provided sterile, disposable and single patient use. The Depth Electrodes (Spencer Probe Depth Electrodes) provide the patient contact device. The Depth Electrodes (Spencer Probe Depth Electrodes) connect to an electrode cable that is applied to the user's equipment. The electrodes are used by physicians.

    AI/ML Overview

    Here's a breakdown of the acceptance criteria and the study information for the Spencer Probe Depth Electrodes, as extracted from the provided text:

    1. Table of Acceptance Criteria and Reported Device Performance

    Hazard AddressedTest Method UsedAcceptance CriterionReported Device Performance (Summary of Test Results)
    Image ArtifactASTM F2119-13No Criteria, Descriptive Statement1.5T: Adoption from 3.0T tests since 3.0T is the worst-case. 3.0T: Image distortion of 19 mm from the edge of the device.
    Magnetically Induced Displacement ForceASTM F2052-15
    Ask a Question

    Ask a specific question about this device

    K Number
    K213170
    Date Cleared
    2023-04-18

    (567 days)

    Product Code
    Regulation Number
    882.1330
    Reference & Predicate Devices
    Why did this record match?
    510k Summary Text (Full-text Search) :

    1612102 Israel

    Re: K213170

    Trade/Device Name: SENSOSEEG Depth Electrodes Regulation Number: 21 CFR 882.1330
    the word "MEDICAL" in a smaller, light blue font.

    Classification Name:

    Depth electrode (21 CFR 882.1330
    GZL

    Device Class: II

    Review Panel: Neurological and Physical Medicine

    Regulation Number: 21 CFR 882.1330
    | Same |
    | 2 | Regulation Number | 21 CFR 882.1330

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    Senso Medical Depth Electrodes are intended for temporary (

    Device Description

    The SENSO SEEG Electrode is a smooth electrode with a diameter of 0.8 - 2 mm with a rounded tip. Different configurations exist with diameters of 0.8, 1.1, 1.27, and 2.0 mm. The electrode contacts are made from stainless-steel that can be 1.5mm, 2.0, and 3.0 mm long, with a total exploration length varying from (22 - 82 mm) according to the electrode reference. The total length of the electrodes range from 360 mm to 410 mm long depending on the number of contacts and total exploration length of the electrodes. The electrodes come in 3 main configurations, but can be customized to the parameters mentioned above based on the application need.

    AI/ML Overview

    This FDA 510(k) summary provides information on the SENSOSEEG Depth Electrodes. However, it does not include detailed acceptance criteria or a study that specifically proves the device meets those criteria in the typical format of a diagnostic algorithm's performance study.

    This document is a premarket notification for a medical device (depth electrodes), not a diagnostic algorithm. Therefore, the "acceptance criteria" and "study" described are focused on the device's physical and functional properties, and its substantial equivalence to predicate devices, rather than on diagnostic performance metrics like accuracy, sensitivity, or specificity common to AI/ML software.

    The acceptance criteria are implied by the comparison to predicate devices and the non-clinical testing performed.

    Here's an attempt to categorize the information based on your request, keeping in mind the nature of this submission:


    1. A table of acceptance criteria and the reported device performance

    Since this is a physical medical device (depth electrodes), the "acceptance criteria" are related to its design specifications, material properties, and functional performance, rather than diagnostic accuracy. The "reported device performance" is largely demonstrated by showing equivalence to legally marketed predicate devices through bench testing and material comparison.

    Acceptance Criterion (Implied)Reported Device Performance (as demonstrated by comparison and testing)
    Intended Use (Temporary recording, monitoring, stimulation of electrical brain signals)Identical to all predicate devices (DIXI Medical Microdeep Depth Electrode (K170959), Ad-tech depth electrodes (K964644), PMT Depthalon Electrodes (K802152)).
    Clinical Application (Placement in subsurface brain for recording, monitoring, stimulation)Identical to DIXI Medical and Ad-tech depth electrodes.
    Contraindications (Patients at risk for infection or unsafe surgical procedures)Identical to Ad-tech depth electrodes.
    Single-patient use, DisposableIdentical to all predicate devices.
    Provided SterileIdentical to all predicate devices; EO Sterilization validated.
    Environment of Use (Intraoperative and Neurological monitoring locations)Identical to all predicate devices.
    Duration of Use (
    Ask a Question

    Ask a specific question about this device

    K Number
    K222706
    Date Cleared
    2022-12-06

    (90 days)

    Product Code
    Regulation Number
    882.1330
    Reference & Predicate Devices
    Why did this record match?
    510k Summary Text (Full-text Search) :

    92110

    Re: K222706

    Trade/Device Name: iCE-SG2 Subcutaneous Electrode Kit Regulation Number: 21 CFR 882.1330
    |
    | Regulation Number: | 21 CFR 882.1330
    subsurface level of the brain. | |
    | Product Codes /
    Regulation Number | GZL / 21 CFR 882.1330
    | GZL / 21 CFR 882.1330

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    iCE-SG2 Subcutaneous Electrode Kit is intended for temporary (

    Device Description

    The iCE-SG2 Subcutaneous Electrode Kit is intended for temporary (

    AI/ML Overview

    The document describes the iCE-SG2 Subcutaneous Electrode Kit and its substantial equivalence to a predicate device (iCE-SG Subcutaneous Electrode Arrays, K201678). The acceptance criteria and the study that proves the device meets them are primarily focused on biocompatibility and performance (bench), as this is a medical device for recording electrical signals from the brain.

    Here's the breakdown of the requested information:

    1. Table of Acceptance Criteria and Reported Device Performance

    Acceptance CriteriaReported Device Performance
    Biocompatibility: Meet ISO 10993 standards and establish biological safety.Biocompatibility evaluation conducted within risk management framework and in compliance with ISO 10993 standards. Evaluation included relevant data sources related to biological safety of finished device testing of previously cleared product (K201678) and kit components with a history of safe biological use. Conclusion: Biological safety established.
    Performance Testing (Bench): Demonstrate reproducibility in electrode insertion, stability of electrode array position, and removal from subcutaneous space. Also, pre-insertion and post-removal impedance testing should be performed.A cadaver study was conducted using ten electrodes. Functions associated with electrode array insertion, stability, and removal were shown to perform as expected. Pre-insertion and post-removal impedance testing was performed. Conclusion: All 10 out of 10 electrode arrays performed successfully based on prespecified criteria.

    2. Sample Size Used for the Test Set and Data Provenance

    • Test Set Sample Size: 10 electrodes were used in the cadaver study for performance testing.
    • Data Provenance: The document does not explicitly state the country of origin. The study was a "cadaver study," implying human cadavers, and is presented as part of a U.S. FDA 510(k) submission, suggesting it was conducted to U.S. regulatory standards. It is a prospective evaluation of the new device's performance.

    3. Number of Experts Used to Establish Ground Truth for the Test Set and Qualifications of Those Experts

    The document does not mention the use of experts to establish a "ground truth" in the traditional sense for the performance testing. The performance criteria (reproducibility of insertion, stability, removal, and impedance measurements) are objective and measured directly, not subject to expert interpretation for ground truth.

    4. Adjudication Method for the Test Set

    Not applicable, as a traditional ground truth based on expert consensus was not established for the performance testing. The assessment of successful performance was based on pre-specified objective criteria.

    5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was Done, If so, What Was the Effect Size of How Much Human Readers Improve with AI vs Without AI Assistance

    Not applicable. This device is an electrode kit for recording electrical signals, not an AI-powered diagnostic tool requiring human reader interpretation or MRMC studies.

    6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done

    Not applicable. This is a physical medical device, not an algorithm.

    7. The Type of Ground Truth Used (Expert Consensus, Pathology, Outcomes Data, etc.)

    The "ground truth" for the performance study was based on objective, pre-specified criteria and measurements from the cadaver study (e.g., successful insertion, stability, removal, and impedance values). For biocompatibility, it was based on compliance with ISO 10993 standards and a history of safe biological use for components.

    8. The Sample Size for the Training Set

    Not applicable. This device is not an AI algorithm that requires a training set.

    9. How the Ground Truth for the Training Set Was Established

    Not applicable. This device is not an AI algorithm.

    Ask a Question

    Ask a specific question about this device

    K Number
    K222404
    Date Cleared
    2022-10-20

    (72 days)

    Product Code
    Regulation Number
    882.1330
    Reference & Predicate Devices
    Why did this record match?
    510k Summary Text (Full-text Search) :

    Eden Prairie, MN 55344

    Re: K222404

    Trade/Device Name: Evo® sEEG System Regulation Number: 21 CFR 882.1330
    |
    | Device Regulation Number: | 21 CFR § 882.1330
    | 21 CFR § 882.1330

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The Evo® sEEG System is intended for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain.

    Device Description

    The NeuroOne Evo® sEEG System is comprised of the Evo® sEEG Electrodes (which includes Anchor Bolt Cap and Stylet) accompanying Cable Assemblies, and the Evo® Anchor Bolts. The Evo® sEEG System components are provided sterile and are single use only. The Evo® sEEG Electrodes and Anchor Bolts are temporarily placed (less than 30 days) at the subsurface level of the brain. The system is designed to be used in stereoelectroencephalography (sEEG) procedures.

    The sEEG electrodes, by way of the accompanying cable assemblies, are connected to recording, monitoring, or stimulation/response instrumentation commercially available for use with other sEEG electrodes, including the predicate device.

    The sEEG electrodes are a 0.8mm diameter polyimide electrode with platinum contacts and are available in varying numbers of contacts: 5 to 16 contacts, with an exploration length (recording depth) from 16 to 80mm. The contact height is 2.0mm and spacing is 1.5-3.2mm apart.

    The Evo® Anchor Bolts are available in 20mm, 30mm, and 35mm lengths, can only be used and placed through a small 2.1mm burr hole drilled in the skull, and should be used only when sEEG depth electrodes are warranted.

    AI/ML Overview

    The provided text describes a 510(k) premarket notification for the Evo® sEEG System, focusing on its substantial equivalence to a predicate device, particularly regarding an extended duration of use. The core of the information revolves around biocompatibility testing to support this extended use.

    Here's a breakdown of the requested information:

    1. A table of acceptance criteria and the reported device performance

    The acceptance criteria are implicitly derived from the ISO standards for biocompatibility testing, where "Pass" indicates meeting the acceptance criteria according to the standard. The reported device performance aligns with these "Pass" conclusions.

    Test/StandardAcceptance Criteria (Implicit from "Pass")Reported Device Performance
    Cytotoxicity ISO 10993-5: 2009Non-cytotoxicPass - Non-cytotoxic
    Sensitization ISO 10993-10: 2010Non-sensitizerPass - Non-sensitizer
    Irritation ISO 10993-10: 2010Non-irritantPass - Non-irritant
    Systemic Toxicity ISO 10993-11: 2017Non-toxicPass - Non-toxic
    Material Mediated Pyrogenicity (ISO 10993-11: 2017)Non-pyrogenicPass - Non-pyrogenic
    Implantation ISO 10993-6: 2016Minimal or no reactionPass - Minimal or no reaction
    Hemolysis ISO 10993-4: 2017Non-hemolyticPass - Non-hemolytic
    Genotoxicity ISO 10993-3: 2014Non-mutagenic and Non-clastogenicPass - Non-mutagenic and Non-clastogenic; Pass - Non-mutagenic
    Subacute Toxicity ISO 10993-11: 2017 (Intraperitoneal)Negative for signs of systemic toxicityPass - Considered negative for signs of systemic toxicity
    Subacute Toxicity ISO 10993-11: 2017 (Intravenous)Negative for signs of systemic toxicityPass - Considered negative for signs of systemic toxicity

    2. Sample sized used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)

    The document mentions specific tests, some of which imply sample sizes (e.g., "ISO Guinea Pig Maximization Sensitization" and "Chronic (29 Days) GLP Brain Tissue Implantation Study (Sheep)"), but it does not explicitly state the numerical sample sizes for each test. The data provenance (country of origin, retrospective/prospective) is also not explicitly provided in the given text. These were "performance evaluations... conducted to address the proposed extended duration of use" and "biocompatibility testing ... as part of this 510(k)", implying they were conducted for this submission.

    3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)

    This section is not applicable to the provided document. The study described is a series of biocompatibility tests, not a clinical study involving expert interpretation of medical images or patient outcomes to establish a "ground truth" for a diagnostic device. The "ground truth" here is the biological reaction or material property as determined by standardized laboratory methods (e.g., cytotoxicity, sensitization, implantation response).

    4. Adjudication method (e.g. 2+1, 3+1, none) for the test set

    This section is not applicable. Adjudication methods are typically used in clinical trials or studies where human readers independently assess data and then resolve disagreements. The biocompatibility tests are laboratory-based and follow established protocols.

    5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

    This section is not applicable. The device is an sEEG electrode system, not an AI-powered diagnostic tool. The performance studies detailed are physical and biological evaluations of the device material and function, not its interpretative assistance capabilities for human readers.

    6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

    This section is not applicable. As stated above, the device is an sEEG electrode system, not an algorithm, and therefore, an "algorithm only" performance evaluation is not relevant.

    7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)

    The "ground truth" in this context is the biological and material reaction observed and measured through standardized laboratory tests (e.g., presence/absence of cytotoxicity, level of irritation, tissue response from implantation). This is derived directly from the results of the specific ISO-standardized tests rather than a clinical ground truth like pathology or expert consensus.

    8. The sample size for the training set

    This section is not applicable. The provided document describes device performance testing for regulatory submission, not the development or training of an AI algorithm. Therefore, there is no "training set" in the context of this submission.

    9. How the ground truth for the training set was established

    This section is not applicable for the same reasons as point 8.

    Ask a Question

    Ask a specific question about this device

    K Number
    K220553
    Date Cleared
    2022-09-16

    (200 days)

    Product Code
    Regulation Number
    882.1330
    Reference & Predicate Devices
    Why did this record match?
    510k Summary Text (Full-text Search) :

    Israel

    Re: K220553

    Trade/Device Name: Neuro Omega System, NeuroSmart System Regulation Number: 21 CFR 882.1330
    |
    | CFR section: | 21 CFR 882.1330
    System: Product Code: CFR section: Regulation name: Trade Name: Common Name:
    Classification:

    GZL 21 CFR 882.1330

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The Neuro Omega system with the incorporated Navigation Tool software (the improved HaGuide software), including the Drive Headstage unit, is intended to assist neurosurgeons in the operating room during functional neurosurgery and to record from and stimulate brain motor and sensory neurons and to aid in the placement of depth electrodes.

    The subject device, the Neuro Omega System with the incorporated Navigation Tool software is also intended: - To monitor, record, and display the bioelectric signals produced by muscles, to stimulate peripheral nerves, and to monitor, record, and display the electrical activity produced by nerves to aid the clinician in the diagnosis and prognosis of neuromuscular disease (EMG).

    • To measure, record, and display the electrical activity of the patient's brain obtained from two or more electrodes on the head (EEG).

    • To measure, display and record the electrical activity of the patient's brain obtained from ECOG strip and grid electrodes.

    • To provide stimulation via electrode pairs or a hand-held bipolar probe for use in functional brain mapping procedures during treatment of patients with a seizure disorder.

    The Neuro Omega with the incorporated installed Navigation tool software, is intended for intraoperative use by medical personnel. Within hospitals, laboratories, clinics, or nursing home settings or outside of a medical facility under the direct supervision of a medical professional. The device may also be placed in the intensive care unit or operating room for continuous recording.

    The NeuroSmart System with the incorporated Navigation Tool software, is intended to be used in assisting neurosurgeons, in the operating room during functional neurosurgery, to record from and stimulate brain motor and sensory neurons and to aid in the placement of depth electrodes.

    Device Description

    The Neuro Omega system is designed for different neurosurgery and neurophysiologic clinical applications including recording from and stimulating brain motor and sensory neurons to accurate navigation of electrodes for neurosurgery target localization in treatment of movement disorders by and to aid in the placement of depth electrodes.

    The device is also designed for measuring bioelectric signals produced by muscles and stimulating peripheral nerves to aid in the diagnosis of neuromuscular disease (EMG).

    The device may also be used to measure and record the electrical activity of the patient's brain obtained by placing two or more electrodes on the head (EEG).

    The Neuro Omega System may also be used to measure, display and record the electrical activity of the patient's brain obtained from ECOG strip and grid electrodes.

    The Neuro Omega System may also be used to provide stimulation via electrode pairs or a hand-held bipolar probe for use in functional brain mapping procedures during the treatment of patients with a seizure disorder.

    The subject device, the Neuro Omega incorporated the installed Navigation Tool software (the improved HaGuide software) is a real-time software incorporated in electrophysiological recording and stimulating systems (like: Neuro Omega and NeuroSmart systems).

    The tool is designed to detect the STN region (improved HaGuide Tool as was cleared under K171581 for Neuro Omega & K172042 for NeuroSmart), it detects the entrance and exit boundaries of STN regions. The tool gives the user a stimulation location recommendation. Furthermore, the tool presents real-time graphs of power spectrum density and RMS of STN region.

    The Navigation Tool can aid in the placement of a compatible DBS Lead when the lead is connected to the cleared Alpha Omega Disposable Sterile LeadConfirm (K191739) and to the Neuro Omega System. This feature allows the user to record through the implanted lead and based on the recordings show simple spectral measures (PSD) within the frequency bands of interest. Based on the recordings from the lead, and the NeuroProbe MicroElectrode recordings, this feature shows the correlation in frequency band between both these recordings.

    When the subject device, the Neuro Omega incorporated the installed Navigation tool is connected to the internet, the relevant intraoperative data collected during DBS surgery can be uploaded to Alpha Omega's cloud by the physician for Neurologist use. This information will assist the Neurologist in programming of the Implantable Pulse Generator (IPG).

    Alpha Omega's NeuroSmart system physiological navigation system is accurate, aiding the neurosurgeons during functional neurosurgery for placing Deep Brain Stimulation (DBS) electrodes.

    The NeuroSmart system can record signals from the brain cells or stimulate the brain target zone during the operation procedure.

    The subject device, the NeuroSmart incorporated the installed Navigation Tool software improved HaGuide software) is a real-time software incorporated in (the electrophysiological recording and stimulating systems (like: Neuro Omega and Neuro Smart systems).

    The tool is designed to detect the STN, it detects the entrance and exit boundaries of STN regions. The tool gives the user a stimulation location recommendation. Furthermore, the tool presents real-time graphs of power spectrum density and RMS of each region.

    The Navigation Tool can aid in the placement of a compatible DBS Lead when the lead is connected to the cleared Alpha Omega Disposable Sterile LeadConfirm (K191739) and to the NeuroSmart System. This feature will allow the user to record through the implanted lead and based on the recordings show simple spectral measures (PSD) within the frequency bands of interest.

    Based on the recordings from the lead and the NeuroProbe MicroElectrode recordings, this feature shows the correlation in frequency band between both these recordings.

    When the subject device, the NeuroSmart incorporated the installed Navigation tool is connected to the internet, the relevant intraoperative data collected during DBS surgery can be uploaded to Alpha Omega's cloud by the physician for Neurologist use. This information will assist the Neurologist in programming the Implantable Pulse Generator (IPG).

    The Navigation Tool SW can work in two modes:

      1. The Navigation Tool can be installed on the Neuro Omega/ NeuroSmart Systems.
      1. The Navigation Tool can work as a standalone software, for that purpose it can be installed on external PC to work in off-line mode.

    In both modes the safety and effectiveness of the Neuro Omega and NeuroSmart systems are not compromised, as the Navigation Tool software is a non-blocking software (it doesn't affect the system's functionality even in malfunction). The Navigation Tool software can run in both modes without affecting the Neuro Omega system safety and effectiveness, nor its functionality.

    The main use of the Navigation tool SW when it runs as a standalone software, is for visual purpose only, meaning to receive data from the systems and present it in graphs. No changes are made to the retrieved data. Furthermore, the data will be used for verification only for the neurologist prior to fine-tuning the IPG work mode by using the IPG interface (not Alpha Omega's device).

    The Navigation Tool provides an option to upload raw data and OR reports to the Alpha Omega server.

    • . The raw data include the MER .mpx files and the workspace files that were saved during the surgery by the Neuro Omega or NeuroSmart system (if enabled by the user).
    • The OR report includes all the HaGuide parameters, OR notes, stimulation . assessments, and lead recording.

    The Alpha Omega server adheres to industry cybersecurity standards.

    The Navigation Tool Software in both its modes, as a standalone software and a software installed on Neuro Omega/NeuroSmart systems, can upload data for storage via secured protocols (FTPS, HTTPS) to Alpha Omega server using the internet connectivity.

    Neuro Omega/NeuroSmart software does not upload data to any web server. They are able to connect locally to the Navigation Tool, which is the only channel through which data can be uploaded to Alpha Omega server. The Navigation Tool cannot download or retrieve any data from Alpha Omega server.

    AI/ML Overview

    The provided text describes the regulatory clearance (K220553) for the "Neuro Omega System" and "NeuroSmart System," both incorporating the "Navigation Tool software." The submission focuses on demonstrating substantial equivalence to previously cleared predicate devices (Neuro Omega system K171581 and NeuroSmart System K172042). The primary changes appear to be software updates (bug fixes and internet connectivity for the Navigation Tool) and the addition of the Navigation Tool software itself.

    Here's an analysis of the acceptance criteria and supporting study information based on the provided text:

    Key Takeaway: The document describes a substantial equivalence submission, which relies on non-clinical performance testing (software verification, cybersecurity, EMC) to ensure that the modifications do not raise new safety or effectiveness concerns compared to the predicate devices. It does not contain information about clinical studies (e.g., MRMC studies, human reader improvement with AI assistance, standalone performance on a clinical test set).


    1. Table of Acceptance Criteria and Reported Device Performance

    Note: The provided FDA document focuses on engineering and software verification tests rather than clinical performance metrics in terms of diagnostic accuracy or reader improvement. The "acceptance criteria" presented are primarily for technical functionality and regulatory compliance.

    Acceptance Criteria CategorySpecific Acceptance CriteriaReported Device Performance
    Software/System VerificationInternet Connectivity works according to its intended use without interrupts to the Neuro Omega/NeuroSmart Software incorporated with Navigation Tool software.All tests passed the acceptance criteria, determining the effectiveness of Neuro Omega/NeuroSmart System with Navigation Tool software.
    Functionality of the GUI of the Navigation Tool Software works according to its intended use.All tests passed the acceptance criteria.
    Functionality of the NRMS and PSD Graphs of the Navigation Tool Software works according to its intended use.All tests passed the acceptance criteria.
    Functionality of the HaGuide settings in the Navigation Tool Software works according to its intended use.All tests passed the acceptance criteria.
    Recommendation window functionality verification of the improved HaGuide feature in the Navigation Tool Software.All tests passed the acceptance criteria.
    Lead Correlation feature functionality in the Navigation Tool Software (Online Lead Correlation).All tests regarding the Online Lead Correlation feature passed the acceptance criteria. (Note: Offline lead correlation analysis feature observed as a bug, but noted as not clinically used during surgeries).
    Functionality of the General settings in the Navigation Tool Software works according to its intended use.All tests passed the acceptance criteria.
    Coexistence TestingThe Neuro Omega and NeuroSmart successfully pass the coexistence testing to verify that other devices do not harm the uploading process. The Neuro Omega and NeuroSmart systems operate normally when the connection is down.All tests passed the acceptance criteria.
    CybersecurityAll security check-ups meet/exceed the requirements for all well-known and established regulatory and compliance standards (based on NIST SP 800-115, OSSTMM, OWASP).All tests passed the acceptance criteria.
    Electromagnetic CompatibilityNeuro Omega PC supplier meets IEC 60601-1-2 Medical electrical equipment Part 1-2: General requirements for basic safety and essential performance Collateral Standard: Electromagnetic Compatibility.The Neuro Omega PC passed with no deviation.
    NeuroSmart PC is certified Federal Communications Commission (FCC) according to US CFR Title 47, FCC.Certified Federal Communications Commission (FCC) NeuroSmart PC with no deviation.
    The Neuro Omega/NeuroSmart fulfill the requirements of IEC 60601-1-2:2014 (fourth edition) for electromagnetic compatibility.All tests passed the acceptance criteria (Neuro Omega EMC Report E194610.00, Neuro Omega Medical IEC 60601-1-2 2014, NeuroSmart EMC Report E197560.00).

    2. Sample Size Used for the Test Set and Data Provenance

    The document does not specify a "test set" in the context of clinical data or patient cases. The tests described are non-clinical verification and validation activities conducted on the device hardware and software functionalities. Therefore, sample sizes for such tests would relate to the number of test cases executed rather than patient data. No information is provided regarding the country of origin or whether any data used for internal testing was retrospective or prospective.


    3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts

    Not applicable. This device submission focuses on substantial equivalence based on engineering and software performance tests, not on diagnostic accuracy requiring expert ground truth establishment from patient data.


    4. Adjudication Method for the Test Set

    Not applicable. As described above, the tests are primarily functional and regulatory compliance checks, not clinical studies requiring adjudication of results against a medical ground truth.


    5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

    No. The document makes no mention of a Multi-Reader Multi-Case (MRMC) comparative effectiveness study. The submission is for substantial equivalence of an updated neurophysiological recording and stimulation system with added software functionalities, not for an AI-assisted diagnostic tool designed to improve human reader performance.


    6. If a Standalone (i.e. algorithm only without human-in-the-loop performance) was done

    The "Navigation Tool SW" can work in two modes:

    1. Installed on the Neuro Omega/NeuroSmart Systems.
    2. As a standalone software, installed on an external PC to work in off-line mode for visual purpose only (meaning to receive data from the systems and present it in graphs). No changes are made to the retrieved data. The data will be used for verification only for the neurologist prior to fine-tuning the IPG (Implantable Pulse Generator) work mode by using the IPG interface (not Alpha Omega's device).

    While there is a "standalone" mode for the Navigation Tool, it is explicitly stated that its purpose is for "visual purpose only" and data presentation, not for making standalone diagnostic or treatment recommendations, nor does it perform "algorithm only" performance in a clinical diagnostic sense that would require a dedicated standalone performance study. The core function of the Neuro Omega and NeuroSmart systems remains recording and stimulation.


    7. The Type of Ground Truth Used

    For the non-clinical performance and regulatory compliance tests described, the "ground truth" implicitly refers to:

    • Pre-defined functional requirements and specifications (for software GUI, graph functionality, settings, etc.).
    • Industry standards (ISO 13485, ISO 14971, IEC 60601-1-2).
    • Regulatory guidelines (FDA Guidance for coexistence, NIST SP 800-115, OSSTMM, OWASP for cybersecurity, FCC regulations).

    No clinical "ground truth" (e.g., expert consensus, pathology, outcomes data) is mentioned as being used for the evaluation presented in this document.


    8. The Sample Size for the Training Set

    Not applicable. The document does not describe the development or training of any machine learning or AI models. The Navigation Tool software provides functionalities like detecting STN regions and providing stimulation location recommendations, but the underlying methodology (e.g., rule-based, signal processing, or statistical) and any associated training data are not discussed. The submission focuses on verification of the software's functionality and safety, not on its learning capabilities or dataset-driven performance.


    9. How the Ground Truth for the Training Set was Established

    Not applicable, as no training set or machine learning/AI model training is described in the provided document.

    Ask a Question

    Ask a specific question about this device

    K Number
    K202087
    Manufacturer
    Date Cleared
    2021-11-18

    (478 days)

    Product Code
    Regulation Number
    882.1330
    Reference & Predicate Devices
    Why did this record match?
    510k Summary Text (Full-text Search) :

    K202087

    Trade/Device Name: DIXI Medical Microdeep Micro-Macro Depth Electrodes Regulation Number: 21 CFR 882.1330
    Usual Name: | Depth Electrode |
    | Classification Name: | 21 CFR §882.1330
    -------------------------|
    | Regulation Number | 21 CFR §882.1330
    | 21 CFR §882.1330
    | 21 CFR §882.1330

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The DIXI Medical Microdeep® Micro-Macro Depth Electrodes are intended for temporary (

    Device Description

    The Microdeep® Micro-Macro Depth Electrode is a single patient use, sterile and disposable device. The Microdeep® Micro-Macro Depth Electrode is invasive as it is placed in contact with nerve tissue (brain) and must only be used during an SEEG procedure with Anchor Bolts. The Microdeen® Micro-Macro Depth Electrode is intended to connect to the user's recording. monitoring and stimulation equipment using the Connection System. This product is intended to be used only by physicians in the area of biopotential recording, monitoring and stimulation / response studies who are trained in intracranial neurophysiology. The DIXI Medical Microdeep® Micro-Macro Depth Electrode is comprised of the following components: Macro-contacts, Micro-contacts, Microdrive for micro-contacts, Cap, Connectors for micro and macro-contacts.

    AI/ML Overview

    The provided 510(k) summary for the DIXI Medical Microdeep® Micro-Macro Depth Electrodes details the results of non-clinical testing to demonstrate substantial equivalence to a predicate device.

    1. Table of Acceptance Criteria and Reported Device Performance

    TestAcceptance Criteria (from context)Reported Device Performance
    Dimensional CharacteristicsVerification of electrodes dimensional characteristicsPass
    Mechanical Characteristics- Verification of electrode microdrive functioning
    • Verification of electrode water tightness
    • Verification of cap maintenance on the electrode sheath
    • Verification of the antirotation function of electrode cap
    • Verification of tensile strength of electrode macro-contacts | Pass |
      | Electrical Characteristics | - Verification of the electrical characteristics (contacts continuity, contacts resistance, absence of short-circuit, insulating resistance)
    • Verification of the electrode integrity and electrical functionality after stimulation under worst case charge density | Pass |
      | Device Integrity | - Verification of the absence of alteration of the packaging
    • Verification of the absence of alteration of the electrode | Pass |
      | Comparative Testing | - Comparative test of the tensile strength of the micro-contacts between the predicate device and the subject device
    • Verification of the integrity and the mechanical functionality of the predicate device and the subject device after clinical simulation of use | Pass |
      | Biocompatibility - Cytotoxicity | Non-cytotoxic (per ISO 10993-5) | Non-cytotoxic |
      | Biocompatibility - Sensitization | Non-sensitive (per ISO 10993-10) | Non-sensitive |
      | Biocompatibility - Irritation or intracutaneous reactivity | Negligible irritation (per ISO 10993-10) | Negligible irritation |
      | Biocompatibility - Acute systemic toxicity | Non-toxic (per ISO 10993-11) | Non-toxic |
      | Biocompatibility - Material-mediated pyrogenicity | Non-pyrogenic (per USP) | Non-pyrogenic |
      | Biocompatibility - Sub-acute toxicity | Non-toxic (per ISO 10993-11) | Non-toxic |
      | Biocompatibility - Genotoxicity – Mouse Lymphoma Assay | Non-genotoxic (per OECD guideline No. 490 and ISO 10993-3) | Non-genotoxic |
      | Biocompatibility - Genotoxicity – Bacterial Reverse Mutation | Non-genotoxic (per OECD guideline No. 471 and ISO 10993-3) | Non-genotoxic |
      | Biocompatibility - Indirect (extract) hemolysis | Non-hemolytic (per ASTM F756 and ISO 10993-4) | Non-hemolytic |
      | Biocompatibility - Implantation and neurotoxicity | No or minimal reaction (per ISO 10993-6) | No or minimal reaction |
      | Sterilization | Sterility Assurance Level (SAL) of 10^-6, EO residuals per ISO 10993-7 (per ISO 11135:2014) | SAL of 10^-6 demonstrated; device meets EO residuals |
      | Shelf-life | Shelf-life established based on accelerated and real-time aging | 4 years established |

    2. Sample Size Used for the Test Set and Data Provenance

    The document does not explicitly state the specific sample sizes used for each non-clinical test. The tests were performed in a laboratory setting by DIXI Medical. The data provenance is internal to DIXI Medical (France). All data appears to be prospective as it details performance and safety studies conducted specifically for this submission.

    3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications

    Not applicable. The tests performed are non-clinical, laboratory-based engineering, material, and biological evaluations. There is no "ground truth" derived from expert review in the clinical sense for these types of tests. The "ground truth" for these tests is the defined engineering specifications, material properties, and biological safety standards (e.g., ISO, USP, ASTM, OECD guidelines).

    4. Adjudication Method for the Test Set

    Not applicable. As noted above, these are non-clinical laboratory tests, not clinical studies requiring adjudication of output. The results of the tests are objectively measured against pre-defined criteria in the relevant standards.

    5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done, and Effect Size

    No, a Multi-Reader Multi-Case (MRMC) comparative effectiveness study was not done. This submission is for a medical device (electrode) and relies on non-clinical performance and safety data, as well as a comparison of technological characteristics to a predicate device, rather than a clinical effectiveness study involving human readers and AI.

    6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done

    Not applicable. This device is an electrode, not an AI or algorithm-based system. Therefore, standalone algorithm performance is not relevant.

    7. The Type of Ground Truth Used

    The ground truth for the non-clinical tests is established by:

    • Engineering specifications and standards: For dimensional, mechanical, and electrical characteristics, the "ground truth" is the established design specifications and performance metrics for the device, validated against recognized engineering principles and testing methods.
    • International Standards (ISO, ASTM, OECD) and Pharmacopeia (USP): For biocompatibility, sterilization, and shelf-life, the "ground truth" is defined by the requirements and acceptance criteria outlined in specific international standards and guidelines (e.g., ISO 10993 series, ISO 11135, USP).

    8. The Sample Size for the Training Set

    Not applicable. This device is an electrode, not an AI or algorithm-based system, so there is no training set in the context of machine learning.

    9. How the Ground Truth for the Training Set Was Established

    Not applicable, as there is no training set for this device.

    Ask a Question

    Ask a specific question about this device

    Page 1 of 5